Oppenheimer Boosts United Therapeutics (NASDAQ:UTHR) Price Target to $165.00

Share on StockTwits

United Therapeutics (NASDAQ:UTHR) had its price objective upped by Oppenheimer from $155.00 to $165.00 in a report issued on Thursday morning, The Fly reports. They currently have an outperform rating on the biotechnology company’s stock.

UTHR has been the subject of several other research reports. ValuEngine lowered shares of United Therapeutics from a sell rating to a strong sell rating in a research report on Thursday, July 2nd. Cowen restated a buy rating and issued a $145.00 price objective on shares of United Therapeutics in a research note on Friday, June 12th. BidaskClub downgraded United Therapeutics from a hold rating to a sell rating in a research report on Wednesday, July 15th. Zacks Investment Research raised United Therapeutics from a hold rating to a buy rating and set a $128.00 price target on the stock in a research note on Sunday, May 3rd. Finally, Credit Suisse Group increased their price target on United Therapeutics from $129.00 to $145.00 and gave the stock an outperform rating in a research report on Thursday, June 25th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company’s stock. United Therapeutics currently has an average rating of Hold and a consensus price target of $141.67.

NASDAQ UTHR opened at $111.47 on Thursday. The business’s 50-day moving average price is $117.48 and its 200 day moving average price is $106.45. The company has a current ratio of 7.43, a quick ratio of 8.46 and a debt-to-equity ratio of 0.26. United Therapeutics has a twelve month low of $75.58 and a twelve month high of $127.79. The company has a market capitalization of $4.91 billion, a PE ratio of 11.44 and a beta of 0.86.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, July 29th. The biotechnology company reported $2.41 earnings per share for the quarter, meeting the consensus estimate of $2.41. United Therapeutics had a net margin of 30.04% and a return on equity of 14.90%. The business had revenue of $362.00 million during the quarter, compared to the consensus estimate of $339.97 million. During the same period in the prior year, the firm earned $3.63 earnings per share. The business’s quarterly revenue was down 3.1% compared to the same quarter last year. Equities analysts predict that United Therapeutics will post 10.48 EPS for the current year.

In other United Therapeutics news, Director Tommy G. Thompson sold 3,100 shares of the firm’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $112.56, for a total value of $348,936.00. Following the completion of the sale, the director now directly owns 9,050 shares of the company’s stock, valued at $1,018,668. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Judy D. Olian sold 4,510 shares of the business’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $124.96, for a total value of $563,569.60. Following the completion of the sale, the director now owns 3,490 shares in the company, valued at $436,110.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 242,210 shares of company stock valued at $28,840,232. 10.90% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. CWM LLC increased its holdings in shares of United Therapeutics by 696.2% in the second quarter. CWM LLC now owns 207 shares of the biotechnology company’s stock worth $25,000 after buying an additional 181 shares during the period. Altshuler Shaham Ltd bought a new stake in United Therapeutics during the first quarter worth about $28,000. Signaturefd LLC boosted its holdings in United Therapeutics by 139.6% in the second quarter. Signaturefd LLC now owns 321 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 187 shares in the last quarter. Banque Cantonale Vaudoise bought a new stake in United Therapeutics during the 2nd quarter valued at about $69,000. Finally, First Mercantile Trust Co. purchased a new position in shares of United Therapeutics in the first quarter worth $72,000. 97.99% of the stock is owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Read More: Balanced Fund

The Fly

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.